[{"id":"ea03117e-1915-40c6-8ad5-83f311e92718","acronym":"HEM-iSMART C","url":"https://clinicaltrials.gov/study/NCT05745714","created_at":"2023-02-27T15:01:08.545Z","updated_at":"2024-07-02T16:35:54.631Z","phase":"Phase 1/2","brief_title":"HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05745714 - HEM-iSMART C","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X","pipe":" | ","alterations":" CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation","tags":["JAK2 • CRLF2 • JAK1 • IL7R • STAT5B • P2RY8 • EPOR • PTPN2 • SH2B3 • DDX3X • USP9X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CRLF2 rearrangement • CRLF2 overexpression • IL7R mutation • IGH-CRLF2 fusion • PTPN2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2030","study_completion_date":" 10/01/2030","last_update_posted":"2023-02-27"}]